Opus Genetics, Inc. (IRD) News
Track canonical SquawkNews coverage tagged to IRD, Opus Genetics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
IRD - Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
IRD - Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
EARNINGS | Aug 06, 2026, 11:00 AM UTC
M
IRD Completes Patient Enrollment in Phase 3 Trial
IRD completes enrollment in OPGx-LCA5 trial
EQUITY | Aug 03, 2026, 11:00 AM UTC
H
Analysts Initiate Buys
Analysts initiate buy ratings
EQUITY | Jul 29, 2026, 11:15 AM UTC
L
Opus Genetics sets September timeline for retinal disease trial data
Opus Genetics sets September timeline for retinal disease trial data
EQUITY | Jul 09, 2026, 01:13 PM UTC
L
Opus Genetics Unlocks Key Milestone With US FDA Alignment on OPGx-LCA5 Phase 3, Wedbush Says
() -- Opus Genetics' (IRD) alignment with the US Food and Drug Administration on the design of the registrational phase 3 study of OPGx-LCA5, an investigational gene therapy for a rare inherited retinal disease, marks an
REGULATION | Jul 06, 2026, 07:00 PM UTC
L
Sector Update: Healthcare Stocks Mixed Premarket Monday
() -- Healthcare stocks were mixed premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) up 0.3%. Novartis (NVS) stock was down more than 1% a
MNA | Jul 06, 2026, 01:18 PM UTC
L
Opus Genetics Aligns With FDA In A Type B Rare Disease Meeting On Design Of Its Registrational Phase 3 Clinical Trial Evaluating OPGX-lCA5 F
Opus Genetics has received the meeting minutes from the Type B meeting confirming several key elements of the trial. The Phase 3 study is expected to enroll eight participants who are able to complete microperimetry test
REGULATION | Jul 06, 2026, 11:12 AM UTC